SEC Comment Letter for Scilex Holding (SCLX) — Feb 20, 2026
Scilex Holding Co
Date: Feb. 20, 2026 · CIK: 0001820190 · Accession: 0000000000-26-001753
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Scilex Holding Company Draft Registration Statement on From S-3 Submitted February 13, 2026 CIK No. 0001820190 Dear Henry Ji Ph.D.:
February 20, 2026
Henry Ji, Ph.D. Chief Executive Officer & President Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Elizabeth Razzano, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 20, 2026 Henry Ji, Ph.D. Chief Executive Officer & President Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Re: Scilex Holding Company Draft Registration Statement on From S-3 Submitted February 13, 2026 CIK No. 0001820190 Dear Henry Ji Ph.D.: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Elizabeth Razzano, Esq. </TEXT> </DOCUMENT>